查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1978930

生物技術服務市場：2026-2032年全球市場預測（按服務類型、產品類型、技術、應用和最終用戶分類）

Biotechnology Services Market by Service Type, Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，生技服務市場價值將達到 2,402.4 億美元，到 2026 年將成長至 2,688.3 億美元，到 2032 年將達到 5,310.7 億美元，複合年成長率為 11.99%。

主要市場統計數據
基準年 2025 2402.4億美元
預計年份：2026年 2688.3億美元
預測年份：2032年 5310.7億美元
複合年成長率 (%) 11.99%

對生物技術服務部門進行簡要概述，說明技術創新、業務永續營運和不斷變化的相關人員優先事項之間的相互作用。

在技​​術創新、監管預期變化以及產學研夥伴關係模式不斷發展的推動下，生物技術服務產業正經歷快速變革時期。從基因組定序到細胞療法開發，提供各類服務的機構都在應對日益複雜的價值鏈，其中數據、可重複性和業務永續營運與科學專業知識同等重要。本文概述了買方、供應商和投資者在評估服務能力和成長潛力時應考慮的策略重點。

基因組學、數位技術和生物製程領域的創新融合正在重新定義服務模式，並迫使供應商整合數據驅動的工作流程和可擴展的營運。

生技服務領域的格局正受到多項變革性變化的影響，這些變化正在改變服務提供者的藍圖和買家的行為。首先，先進基因組學和分析技術的興起，正在將以往獨立完成的任務轉變為數據驅動的工作流程。定序能力、自動化PCR、高精度質譜和單細胞分析等技術，使得人們更深入了解生物學，並縮短研究週期。因此，那些將儀器與強大的生物資訊流程相結合的公司正在獲得戰略優勢，因為買家越來越重視能夠縮短研究結果獲取時間的端到端解決方案。

評估近期關稅變化對營運、採購和策略的連鎖影響，以及對供應連續性和區域生產地點選擇的影響。

2025年關稅和貿易措施的實施對生物技術服務供應商的採購、供應鏈規劃和定價趨勢產生了直接和間接的影響。短期來看，進口設備、試劑和特殊耗材關稅的提高增加了依賴跨境採購的機構的總成本。這迫使許多服務提供者重新審視其供應商組合，加快替代供應商的認證流程，並增加庫存緩衝，以防止關鍵項目中斷。因此，由於服務提供者需要在保持服務連續性的同時應對利潤率壓力，這些調整也影響了與客戶的合約談判。

全面的細分洞察，揭示服務類型、最終用戶、技術、應用和產品類型的能力優先級，指南策略定位。

深入的細分分析揭示了不同服務類型、終端用戶、技術、應用和產品類型中存在的競爭壓力、能力差距和機會所在。在服務類型方面，隨著定序量和分析複雜性的增加，包含資料分析和軟體解決方案的生物資訊服務在價值主張中的提案日益凸顯。能夠同時提供發酵和純化服務的生物製程供應商更有能力支持需要規模化和嚴格品管的生物製劑和細胞治療項目。細胞治療服務在同種異體和自體移植管道的發展凸顯了不同的需求。同種異體移植需要可擴展的生產和穩健的供應鏈，而自體移植則更注重快速物流和個人化流程管理。客製化細胞株開發（無論是哺乳動物細胞系還是微生物細胞系）仍然是早期藥物發現和生產的基礎，將其與涵蓋生物製劑和小分子藥物發現的藥物發現服務以及PCR和測序等基因組服務相結合，能夠產生協同效應。

影響採購業務永續營運和協作網路的美洲、歐洲、中東、非洲和亞太地區的區域趨勢和能力叢集。

區域趨勢塑造了競爭格局和投資重點，美洲、歐洲、中東、非洲和亞太地區呈現不同的模式。在美洲，先進的基因組基礎設施、成熟的生物技術生態系統和充裕的創業投資資金推動了服務創新和綜合服務中心的快速形成。該地區受益於緊密的學術機構、成熟的生物技術公司和受託研究機構（CRO）網路，為夥伴關係和轉化研究計畫創造了肥沃的土壤。監管和報銷框架也影響診斷和治療服務的擴張速度，要求服務提供者應對聯邦和州級法規之間錯綜複雜的相互作用。

公司在選擇測試服務提供者時，其策略重點和競爭優勢包括與數位測試服務平台的整合以及對區域能力的投資。

主要服務供應商之間的競爭格局聚焦於功能整合、地域覆蓋數位化加速。那些已將業務從單一服務擴展到整合檢測、生物資訊學和實驗室資訊學的一體化工作流程的公司，正透過簡化計劃管理和提升數據連續性來吸引客戶。新建生物製程設施和區域定序及試劑中心的策略性資本投資，體現了企業縮短前置作業時間和提升服務可靠性的努力。與學術機構和合約研究組織 (CRO) 的合作進一步增強了創新管道和客戶拓展能力。

透過數位整合、供應鏈韌性、夥伴關係關係、監管合規和人才發展，採取可操作且優先的行動來賦能高階主管。

產業領導者應優先考慮一系列切實可行的舉措，以維持競爭力並創造成長機會。首先，他們應投資於整合式數位平台，將儀器輸出與生物資訊學和實驗室資訊學連接起來，從而縮短知識獲取週期並提高可重複性。此外，還應開展人才培養計劃，提昇科學家在資料科學和自動化工作流程方面的技能，使企業能夠最大限度地效用新技術。其次，他們應實現供應商網路多元化，並為關鍵試劑、耗材和儀器建立區域冗餘，以減輕貿易中斷和關稅導致的成本波動的影響。

我們採用了一種嚴謹的混合方法，結合了相關人員訪談、文獻整合、細分分析和區域地圖繪製，以根據可靠的證據得出結論。

本分析的調查方法結合了定性和定量方法，以可靠的證據為基礎得出結論。主要研究包括對服務供應商高階主管、生物製藥和學術實驗室採購人員、採購經理以及監管專家進行結構化訪談，以直接了解決策因素、營運限制和技術採納模式。次要研究整合了同行評審文獻、技術應用說明、監管指南和公司資訊披露，以將主要研究結果置於更廣闊的背景中，並檢驗觀察到的趨勢。

報告調查結果的簡要總結，重點在於將技術和營運彈性與協作策略結合，以確保競爭優勢。

總而言之，隨著技術創新、監管複雜性和供應鏈波動不斷重塑供應商和買家的預期，生物技術服務產業正經歷快速變革。成功的企業往往將實驗室實踐與先進的資訊技術結合，投資於可擴展的生物製程能力，並建立具有韌性的、地域分散的供應鏈。學術界、合約研究機構 (CRO) 和產業界之間的策略合作有望加速轉化研究，並擴大獲得新型治療方法和診斷機會的途徑。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：生技服務市場：依服務類型分類

  • 生物資訊服務
    • 數據分析
    • 軟體解決方案
  • 生物製程
    • 發酵服務
    • 煉油服務
  • 細胞治療服務
    • 異體細胞療法
    • 自體細胞療法
  • 客製化細胞株開發
    • 哺乳動物細胞株
    • 微生物細胞株
  • 藥物發現
    • 生物製劑藥物研發
    • 小分子藥物發現
  • 基因組服務
    • PCR服務
    • 定序服務

第9章：生技服務市場：依產品類型分類

  • 消耗品
    • 板和管
    • 試劑和試劑盒
  • 裝置
    • 顯微鏡
    • 序列器
    • 光譜儀
  • 軟體和服務
    • 生物資訊軟體
    • 實驗室資訊學

第10章：生技服務市場：依技術分類

  • 分析技術
    • 層析法
    • 質譜分析
  • 細胞培養技術
  • 基因組技術
    • 下一代定序
    • PCR技術
  • 成像技術
    • 流式細胞技術
    • 顯微鏡

第11章：生技服務市場：依應用領域分類

  • 診斷
    • 生物標記發現
    • 伴隨診斷
  • 藥物發現
    • 先導藥物最適化
    • 目標識別
  • 研究
    • 基礎研究
    • 轉化研究
  • 治療研發
    • 臨床檢測
    • 臨床前試驗

第12章：生技服務市場：依最終用戶分類

  • 學術研究機構
    • 政府附屬實驗室
    • 大學實驗室
  • 生技公司
    • 現有生技公司
    • Start-Ups
  • 受託研究機構
    • 臨床研究
    • 臨床前研究
  • 製藥公司
    • 大型製藥企業
    • 中小型製藥公司

第13章：生技服務市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：生技服務市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：生技服務市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國生技服務市場

第17章：中國生物技術服務市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • Charles River Laboratories International, Inc.
  • Crown Bioscience, Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • GE HealthCare Technologies Inc.
  • GenScript BIoTech Corporation
  • ICON PLC
  • IQVIA Holdings Inc.
  • Laboratory Corporation of America Holdings
  • PerkinElmer, Inc.
  • SGS SA
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-521BAA36EA71

The Biotechnology Services Market was valued at USD 240.24 billion in 2025 and is projected to grow to USD 268.83 billion in 2026, with a CAGR of 11.99%, reaching USD 531.07 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 240.24 billion
Estimated Year [2026] USD 268.83 billion
Forecast Year [2032] USD 531.07 billion
CAGR (%) 11.99%

A concise orientation to the biotechnology services sector describing the interplay of technological innovation operational resilience and evolving stakeholder priorities

The biotechnology services landscape is experiencing a period of accelerated change driven by technological innovation, shifting regulatory expectations, and evolving partnerships across industry and academia. Organizations providing services from genomic sequencing to cell therapy development are navigating a more complex value chain in which data, reproducibility, and operational resilience have become equally important to scientific expertise. This introduction frames the strategic priorities that buyers, providers, and investors must weigh when evaluating service capabilities and growth potential.

Over the coming chapters, the report unpacks how advances in instrumentation, computational biology, and automated bioprocessing are redefining what constitutes competitive advantage in the sector. It highlights how service providers are responding by expanding offerings, investing in digital platforms, and deepening collaborations with contract research entities and academic centers. By situating these dynamics within the broader context of supply chain pressures and regulatory evolution, the introduction prepares readers for the deeper analysis that follows.

How converging genomic, digital, and bioprocessing innovations are redefining service models and forcing providers to integrate data driven workflows with scalable operations

The biotechnology services landscape is being reshaped by several transformative shifts that are altering provider roadmaps and buyer behavior. First, the ascendancy of advanced genomic and analytical technologies is turning previously discrete tasks into data-driven workflows; sequencing throughput, PCR automation, mass spectrometry precision, and single-cell approaches are enabling richer biological insights and compressing timelines. Consequently, companies that integrate instrumentation with robust bioinformatics pipelines are gaining strategic advantage as buyers increasingly prioritize end-to-end solutions that reduce time to insight.

Second, the proliferation of cell therapy and biologics programs is forcing innovation across bioprocessing and custom cell line development. The operational demands of autologous and allogeneic cell therapies have spurred investment in scalable fermentation, purification, and closed-system manufacturing approaches. Third, the acceleration of digital transformation-cloud-enabled data management, lab informatics, and AI-driven analysis-has elevated software and services to a keystone role in service portfolios. Finally, changing regulatory expectations and increasing emphasis on reproducibility and data provenance are prompting providers to strengthen quality systems, adopt standardized protocols, and pursue deeper partnerships with academic and clinical stakeholders. Together, these shifts are driving convergence between traditional laboratory services and integrated digital-bioprocessing platforms, setting the stage for the next phase of industry competition and collaboration.

Assessing the cascading operational, procurement, and strategic consequences of recent tariff changes and their implications for supply continuity and regional production choices

The implementation of tariffs and trade measures in 2025 has introduced immediate and secondary effects across procurement, supply chain planning, and pricing dynamics for biotechnology service providers. In the short term, increased duties on imported instruments, reagents, and specialized consumables have elevated landed costs for organizations that rely on cross-border sourcing. This has prompted many providers to reexamine supplier portfolios, accelerate qualification of alternative vendors, and to increase inventory buffers to insulate critical programs from disruption. In turn, these adjustments have influenced contractual negotiations with clients as providers seek to manage margin pressure while maintaining service continuity.

Over a longer horizon, tariffs have reshaped investment patterns and strategic decisions around regional production and localization. Some instrument manufacturers and reagent suppliers have signaled intentions to diversify manufacturing footprints or to develop regional hubs, which could mitigate exposure to trade policy volatility. At the same time, buyers are evaluating nearshoring options and seeking suppliers with robust multi-region supply chains. Regulatory compliance and customs complexity have added administrative overhead, encouraging larger providers to invest in dedicated trade compliance functions and digital procurement platforms. Importantly, these trade dynamics have amplified the value of vertically integrated service providers and those that offer bundled solutions including software and local support, since such models reduce reliance on cross-border shipments for routine operations. As a result, stakeholders are balancing the need for cost control against the imperative to preserve access to best-in-class technologies and specialized reagents.

Comprehensive segmentation insights that reveal capability priorities across service types end users technologies applications and product categories to inform strategic positioning

Insightful segmentation analysis reveals where competitive pressures, capability gaps, and opportunity vectors lie across service types, end users, technologies, applications, and product types. Within service type, bioinformatics services-comprising data analysis and software solutions-are increasingly central to value propositions as sequencing volumes and analytic complexity rise. Bioprocessing providers that can deliver both fermentation and purification services are better positioned to support biologics and cell therapy programs that require scale and stringent quality controls. The evolution of cell therapy services across allogeneic and autologous pathways highlights divergent needs: allogeneic approaches demand scalable manufacturing and supply chain robustness while autologous workflows emphasize rapid logistics and individualized process control. Custom cell line development, whether mammalian or microbial, remains foundational for early discovery and production, and its integration with drug discovery services-spanning biologics and small molecule discovery-creates synergies when paired with genomic services such as PCR and sequencing.

From an end user perspective, academic and research institutes including government and university labs continue to drive methodological innovation and early-stage validation, while biotech companies-both established firms and startups-translate these advances into commercial pipelines. Contract research organizations supporting clinical and preclinical studies are increasingly collaborating with service providers to deliver comprehensive development programs. Pharmaceutical companies with diverse portfolios, including large global firms and mid-size and small pharmas, prioritize partners that can meet rigorous regulatory expectations and provide predictable delivery. Technology segmentation underscores the importance of analytical techniques like chromatography and mass spectrometry for quality and characterization, while cell culture technologies-ranging from two-dimensional systems to three-dimensional culture-are essential for translational relevance. Genomic technologies, including next generation sequencing and PCR, remain critical for discovery and diagnostics, and imaging technologies such as flow cytometry and microscopy provide indispensable phenotypic context. Application-driven differentiation is evident across diagnostic workstreams focused on biomarker discovery and companion diagnostics, drug discovery efforts centered on lead optimization and target identification, research initiatives spanning basic to translational studies, and therapeutic development activities that encompass both preclinical testing and clinical trial readiness. Finally, product type analysis shows that consumables like plates, tubes, reagents and kits underpin daily laboratory workflows, while instruments including microscopes, sequencers, and spectrometers represent high-value capital investments, and software and services such as bioinformatics software and lab informatics deliver the connective tissue that turns data into actionable insight.

Regional dynamics and capability clusters across the Americas Europe Middle East & Africa and Asia Pacific that influence sourcing operational resilience and collaborative networks

Regional dynamics are shaping competitive landscapes and investment priorities, with distinct patterns emerging across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, advanced genomic infrastructure, a mature biotechnology ecosystem, and deep venture funding have driven rapid service innovation and the formation of integrated service hubs. This region benefits from a dense network of academic centers, established biotech firms, and contract research organizations, creating fertile ground for partnerships and translational initiatives. Regulatory agencies and reimbursement frameworks also influence the pace at which diagnostics and therapeutic services scale, and providers must navigate a complex patchwork of federal and state-level requirements.

Europe Middle East & Africa presents a mosaic of capabilities with leading academic institutions and specialized CROs concentrated in core hubs, while other areas are rapidly developing infrastructure and talent. Regulatory harmonization across certain jurisdictions has aided cross-border collaboration, though geopolitical factors and supply chain considerations create variability in procurement strategies. In contrast, Asia-Pacific has become a center for manufacturing scale, reagent production, and emerging service providers that combine cost competitiveness with growing technical expertise. Governments across the region are investing in genomics, cell therapy, and biomanufacturing capabilities, and buyers increasingly source both routine consumables and sophisticated services from Asia-Pacific partners. Across all regions, connectivity through digital platforms and cross-border collaborations is reinforcing the global nature of the services ecosystem even as organizations pursue regional resilience and localized capabilities.

Strategic company priorities and competitive differentiators that determine provider selection including integration of laboratory services digital platforms and regional capacity investments

Competitive dynamics among leading service providers are centered on capabilities integration, geographic footprint, and digital enablement. Companies that have expanded beyond single-service offerings to provide bundled workflows-combining laboratory execution with bioinformatics and lab informatics-are capturing client interest by simplifying project management and improving data continuity. Strategic investments in capacity, whether through new facilities for bioprocessing or regional hubs for sequencing and reagents, reflect a drive to reduce lead times and enhance service reliability. Partnerships with academic institutions and CROs further strengthen pipelines for innovation and client referrals.

Many providers are differentiating through targeted service verticalization, specializing in areas such as cell therapy manufacturing, clinical-grade sequencing, or bespoke cell line development for complex biologics. At the same time, technology partnerships and licensing arrangements for advanced analytical tools and AI platforms are enabling faster data interpretation and predictive process insights. Competitive positioning increasingly hinges on service quality, regulatory track record, and the ability to demonstrate reproducible outcomes. Firms that balance technical excellence with commercial agility-offering flexible contracting, transparent data governance, and clear regulatory pathways-are most likely to sustain long-term client relationships.

Practical and prioritized actions for executives to strengthen capabilities through digital integration supply chain resilience partnerships regulatory readiness and workforce upskilling

Industry leaders should prioritize a set of actionable initiatives to maintain competitive relevance and to unlock growth opportunities. First, invest in integrated digital platforms that connect instrument output to bioinformatics and lab informatics, thereby shortening insight cycles and improving reproducibility. This approach should be complemented by workforce development programs that upskill scientists in data science and automated workflows, ensuring organizations maximize the utility of new technologies. Second, diversify supplier networks and build regional redundancy for critical reagents, consumables, and instruments to mitigate the impact of trade disruptions and tariff-driven cost volatility.

Third, pursue targeted collaborations with academic centers and CROs to co-develop capabilities in high-growth areas such as cell therapy and advanced genomic assays. Fourth, enhance regulatory and quality infrastructures to support rapid entry into clinical and diagnostic pathways; embedding compliance expertise within project teams will reduce friction during translational phases. Fifth, explore modular service models that allow clients to select discrete capabilities or bundled end-to-end workflows depending on program maturity. Finally, prioritize sustainability and traceability in procurement and operations, as buyers and regulators increasingly expect demonstrable commitments to ethical sourcing and environmental stewardship. By sequencing these initiatives and aligning them with clear metrics for operational performance and client satisfaction, leaders can convert strategic intent into measurable outcomes.

A rigorous mixed methods approach combining stakeholder interviews literature synthesis segmentation analysis and regional mapping to ensure robust evidence based conclusions

The research methodology underpinning the analysis combined qualitative and quantitative techniques to ensure robust, evidence-based conclusions. Primary research included structured interviews with senior executives across service providers, buyers in biopharma and academic laboratories, procurement leads, and regulatory specialists, enabling direct insights into decision drivers, operational constraints, and technology adoption patterns. Secondary research synthesized peer-reviewed literature, technology application notes, regulatory guidance, and company disclosures to contextualize primary findings and to validate observed trends.

Data triangulation and cross-validation were applied to reconcile differing perspectives and to identify consistent signals across sources. Segmentation analysis was performed by dissecting service lines, end user types, technology platforms, applications, and product types, which allowed for granular interpretation of capability gaps and strategic opportunities. The methodology also incorporated regional mapping to capture geographic variations in infrastructure and policy. Quality assurance measures included peer review by subject matter experts and sensitivity checks to ensure that conclusions remained robust under alternative assumptions. This mixed-methods approach supports practical recommendations and provides a defensible basis for strategic decision-making.

Concise synthesis of the report findings emphasizing integration of technology operational resilience and collaborative strategies to secure competitive advantage

In summary, the biotechnology services sector is evolving rapidly as technological innovation, regulatory complexity, and supply chain dynamics converge to redefine provider and buyer expectations. Success will favor organizations that integrate laboratory execution with advanced informatics, invest in scalable bioprocessing capabilities, and build resilient, regionally diversified supply chains. Strategic collaborations across academia, CROs, and industry will accelerate translational work and expand access to emerging therapeutic and diagnostic opportunities.

Looking forward, providers that balance technical excellence with operational discipline-ensuring reproducibility, compliance, and timely delivery-will win sustained client trust. Equally important will be the ability to adapt commercial models to client needs, offering modular services or full-service programs as appropriate. By executing against these priorities, stakeholders can better navigate policy shifts, capital constraints, and technological disruption while delivering the high-quality services that modern life sciences research and development demand.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biotechnology Services Market, by Service Type

  • 8.1. Bioinformatics Services
    • 8.1.1. Data Analysis
    • 8.1.2. Software Solutions
  • 8.2. Bioprocessing
    • 8.2.1. Fermentation Services
    • 8.2.2. Purification Services
  • 8.3. Cell Therapy Services
    • 8.3.1. Allogeneic Cell Therapy
    • 8.3.2. Autologous Cell Therapy
  • 8.4. Custom Cell Line Development
    • 8.4.1. Mammalian Cell Line
    • 8.4.2. Microbial Cell Line
  • 8.5. Drug Discovery
    • 8.5.1. Biologics Discovery
    • 8.5.2. Small Molecule Discovery
  • 8.6. Genomic Services
    • 8.6.1. PCR Services
    • 8.6.2. Sequencing Services

9. Biotechnology Services Market, by Product Type

  • 9.1. Consumables
    • 9.1.1. Plates And Tubes
    • 9.1.2. Reagents And Kits
  • 9.2. Instruments
    • 9.2.1. Microscopes
    • 9.2.2. Sequencers
    • 9.2.3. Spectrometers
  • 9.3. Software And Services
    • 9.3.1. Bioinformatics Software
    • 9.3.2. Lab Informatics

10. Biotechnology Services Market, by Technology

  • 10.1. Analytical Techniques
    • 10.1.1. Chromatography
    • 10.1.2. Mass Spectrometry
  • 10.2. Cell Culture Technologies
  • 10.3. Genomic Technologies
    • 10.3.1. Next Generation Sequencing
    • 10.3.2. PCR Technology
  • 10.4. Imaging Technologies
    • 10.4.1. Flow Cytometry
    • 10.4.2. Microscopy

11. Biotechnology Services Market, by Application

  • 11.1. Diagnostic
    • 11.1.1. Biomarker Discovery
    • 11.1.2. Companion Diagnostics
  • 11.2. Drug Discovery
    • 11.2.1. Lead Optimization
    • 11.2.2. Target Identification
  • 11.3. Research
    • 11.3.1. Basic Research
    • 11.3.2. Translational Research
  • 11.4. Therapeutic Development
    • 11.4.1. Clinical Trials
    • 11.4.2. Preclinical Testing

12. Biotechnology Services Market, by End User

  • 12.1. Academic And Research Institutes
    • 12.1.1. Government Labs
    • 12.1.2. University Labs
  • 12.2. Biotech Companies
    • 12.2.1. Established Biotech
    • 12.2.2. Startups
  • 12.3. Contract Research Organizations
    • 12.3.1. Clinical Research
    • 12.3.2. Preclinical Research
  • 12.4. Pharmaceutical Companies
    • 12.4.1. Big Pharma
    • 12.4.2. Mid Size And Small Pharma

13. Biotechnology Services Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biotechnology Services Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biotechnology Services Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biotechnology Services Market

17. China Biotechnology Services Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agilent Technologies, Inc.
  • 18.6. Charles River Laboratories International, Inc.
  • 18.7. Crown Bioscience, Inc.
  • 18.8. Danaher Corporation
  • 18.9. Eurofins Scientific SE
  • 18.10. GE HealthCare Technologies Inc.
  • 18.11. GenScript Biotech Corporation
  • 18.12. ICON PLC
  • 18.13. IQVIA Holdings Inc.
  • 18.14. Laboratory Corporation of America Holdings
  • 18.15. PerkinElmer, Inc.
  • 18.16. SGS SA
  • 18.17. Thermo Fisher Scientific Inc.
  • 18.18. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOTECHNOLOGY SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOTECHNOLOGY SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOTECHNOLOGY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOTECHNOLOGY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SOFTWARE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SOFTWARE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOPROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOPROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOPROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOPROCESSING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY FERMENTATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY FERMENTATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY FERMENTATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PURIFICATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PURIFICATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PURIFICATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL THERAPY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL THERAPY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL THERAPY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL THERAPY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CUSTOM CELL LINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CUSTOM CELL LINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CUSTOM CELL LINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CUSTOM CELL LINE DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MAMMALIAN CELL LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MAMMALIAN CELL LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MAMMALIAN CELL LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROBIAL CELL LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROBIAL CELL LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROBIAL CELL LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOLOGICS DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOLOGICS DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOLOGICS DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SMALL MOLECULE DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SMALL MOLECULE DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SMALL MOLECULE DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC SERVICES, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PCR SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PCR SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PCR SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PLATES AND TUBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PLATES AND TUBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PLATES AND TUBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROSCOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROSCOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROSCOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SPECTROMETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SPECTROMETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SPECTROMETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY LAB INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY LAB INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY LAB INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ANALYTICAL TECHNIQUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ANALYTICAL TECHNIQUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ANALYTICAL TECHNIQUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ANALYTICAL TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL CULTURE TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL CULTURE TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL CULTURE TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PCR TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PCR TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PCR TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY IMAGING TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY IMAGING TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY TRANSLATIONAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY TRANSLATIONAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY TRANSLATIONAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRECLINICAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRECLINICAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GOVERNMENT LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY GOVERNMENT LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY UNIVERSITY LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY UNIVERSITY LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY UNIVERSITY LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ESTABLISHED BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ESTABLISHED BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY ESTABLISHED BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY STARTUPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY STARTUPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY STARTUPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CLINICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY CLINICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRECLINICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRECLINICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIG PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIG PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIG PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MID SIZE AND SMALL PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MID SIZE AND SMALL PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY MID SIZE AND SMALL PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL BIOTECHNOLOGY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOPROCESSING, 2018-2032 (USD MILLION)
  • TABLE 218. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL THERAPY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 219. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY CUSTOM CELL LINE DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 220. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 221. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC SERVICES, 2018-2032 (USD MILLION)
  • TABLE 222. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY ANALYTICAL TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 237. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS BIOTECHNOLOGY SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOPROCESSING, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL THERAPY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY CUSTOM CELL LINE DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC SERVICES, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY ANALYTICAL TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 258. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 260. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 264. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOPROCESSING, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL THERAPY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY CUSTOM CELL LINE DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC SERVICES, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 278. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY ANALYTICAL TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 280. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 282. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 284. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 286. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 290. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOINFORMATICS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY BIOPROCESSING, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY CELL THERAPY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY CUSTOM CELL LINE DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY GENOMIC SERVICES, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY SERVICES MARKET SIZE, BY CONSU